Full Breakdown
Congo Launches Ervebo Vaccination Amid Fastest-Growing Ebola Outbreak
8/29/2026, 12:24:09 AM
Core Event: Vaccination Campaign Begins
On August 28, 2026 health authorities in the Democratic Republic of Congo officially launched an Ebola vaccination drive in Kisangani, the capital of Tshopo province. The campaign prioritises health-care workers and other frontline responders, who are receiving the Ervebo vaccine under a compassionate-use program despite the outbreak being caused by the Bundibugyo strain, for which no licensed vaccine exists. The rollout is planned for 14 health zones across Tshopo, Bas-Uele and Haut-Uele provinces.
Background & Context
The current epidemic is driven by the Bundibugyo species of Ebola virus, a rare variant not seen since 2012. The World Health Organization (WHO) has warned that the outbreak is “out of control” and on track to surpass the 2014-2016 West Africa epidemic. Insecurity, population displacement, a health-workers’ strike and intense movement of people have hampered response efforts. The first known case was a nurse who developed symptoms on April 24, indicating weeks of undetected transmission before the outbreak was declared in mid-May.
Data & Statistics
- Government figures reported 5,713 confirmed cases and 2,744 deaths (?48 % fatality) in early August, while later updates listed 5,794 cases and 2,786 deaths. The BBC noted 5,514 cases and 2,642 deaths as of August 23.
- The outbreak now affects 60 health zones in six provinces: Ituri, North Kivu, South Kivu, Tshopi, Haut-Uele and Bas-Uele.
- More than 50,000 doses of Ervebo have been received; WHO approved 70,000 doses for use in Congo, allocating roughly 50,000 for frontline workers and 20,000 for a clinical trial to assess cross-protection against Bundibugyo.
- The vaccination effort targets 14 health zones, aiming to protect health personnel and contacts of patients.
Official Statements & Responses
Health Minister Roger Kamba announced the launch, emphasizing protection for frontline staff and contacts of patients. The WHO reiterated that Ervebo may offer partial protection because the two Ebola strains are related, but its effectiveness against Bundibugyo remains under study. Placide Mbala Kingebeni, Africa CDC’s director for research, clinical trials and innovation, said data will be collected throughout the campaign to evaluate vaccine performance. Dr. Boghuma K. Titanji, an infectious-diseases physician at Emory University, explained that the decision to deploy Ervebo reflects the urgency of the outbreak and the need for any tool that could confer partial benefit while specific Bundibugyo vaccines are still in early-phase trials.
Conflicting Reports & Gaps
Sources differ on the exact case and death totals, ranging from 5,513 to 5,794 confirmed infections and from 2,642 to 2,786 deaths. No source provides definitive evidence that Ervebo prevents illness from the Bundibugyo strain; efficacy remains an “attributed claim” pending trial results. Additionally, while the campaign plans to cover 14 health zones, the precise number of individuals to be vaccinated has not been disclosed.
What’s Next
Parallel to the Ervebo rollout, the University of Oxford’s Vaccine Group and Moderna have begun Phase I trials of Bundibugyo-specific vaccines, with results expected later this year. Data from the compassionate-use campaign will inform WHO and Africa CDC assessments of cross-protection and guide future vaccination strategies.
